Literature DB >> 30523640

Prognostic relevance of miR-137 and its liver microenvironment regulatory target gene AFM in hepatocellular carcinoma.

Qian Wei1, Lin Zhao1, Longyang Jiang1, Jia Bi1, Zhaojin Yu1, Lan Zhao1, Xinyue Song1, Mingli Sun1, Yuzong Chen2, Minjie Wei1.   

Abstract

MiR-137 has been identified as potential hepatocellular carcinoma (HCC) prognostic biomarkers. Highly relevant HCC prognostic biomarkers may be derived from combinations of miR-137 with its target genes involved in the regulation of liver microenvironment. This study aimed at the discovery of such a combination with improved HCC prognosis performance than miR-137 or its target gene alone in a significantly higher number of HCC patients than previous studies. Analysis of the differentially expressed micro RNAs (miRNAs) between cancer and noncancer tissues reconfirmed miR-137 to be among the most relevant prognostic miRNAs and the data of 375 HCC patients and 50 normal cases were from the Cancer Genome Atlas (TCGA) data sets. Target genes were identified by the established search methods and Kaplan-Meier survival analysis of HCC patients was used to evaluate the overall survival (OS) and recurrence-free survival (RFS). Cox proportional hazards regression indicated that the miR-137 and its target gene AFM combination is an independent prognostic factor for the OS and RFS in HCC. In vitro experiments validated that miR-137 could bind to 3'-untranslated region of the AFM and promote the invasion and metastasis of HCC cell lines. The expressions of miR-137 and its liver microenvironment regulatory target gene AFM in combination significantly correlated with HCC progression in a higher number of patients than in previous studies, which suggested their potential as prognostic biomarkers for HCC.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  AFM; combination biomarkers; hepatocellular carcinoma; miR-137; microenvironment; prognosis

Mesh:

Substances:

Year:  2018        PMID: 30523640     DOI: 10.1002/jcp.27855

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

Review 1.  Epidemiological and etiological variations in hepatocellular carcinoma.

Authors:  Evangelista Sagnelli; Margherita Macera; Antonio Russo; Nicola Coppola; Caterina Sagnelli
Journal:  Infection       Date:  2019-07-25       Impact factor: 3.553

2.  Prognostic Value of miR-137 in Children with Medulloblastoma and its Regulatory Effect on Tumor Progression.

Authors:  Wenyuan Ji; Xuan Zhe; Lusheng Li; Yang Cheng; Xueling Zhao; Ping Liang; Chunxi Long; Jianjun Zhou
Journal:  Neuromolecular Med       Date:  2021-08-18       Impact factor: 3.843

3.  Investigation of Potential Molecular Biomarkers for Diagnosis and Prognosis of AFP-Negative HCC.

Authors:  Zijing Liu; Youwei Pu; Yixi Bao; Song He
Journal:  Int J Gen Med       Date:  2021-08-10

4.  Bioinformatic analysis and in vitro validation of a five-microRNA signature as a prognostic biomarker of hepatocellular carcinoma.

Authors:  Wang Li; Xiangshuo Kong; Tao Huang; Lujun Shen; Peihong Wu; Qi-Feng Chen
Journal:  Ann Transl Med       Date:  2020-11

5.  MicroRNA-137-3p Improves Nonalcoholic Fatty Liver Disease through Activating AMPKα.

Authors:  Yuanjie Yu; Chunping He; Shiyun Tan; Mengjun Huang; Yitian Guo; Ming Li; Qian Zhang
Journal:  Anal Cell Pathol (Amst)       Date:  2021-12-29       Impact factor: 2.916

6.  MicroRNA-587 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Targeting Ribosomal Protein SA.

Authors:  Miao Chen; Duo Wang; Junjie Liu; Zhizhan Zhou; Zhanling Ding; Lianfeng Liu; Danke Su; Hang Li
Journal:  Biomed Res Int       Date:  2020-09-05       Impact factor: 3.411

7.  Identification of Differentially Expressed MicroRNAs and Their Potential Target Genes in Adipose Tissue from Pigs with Highly Divergent Backfat Thickness.

Authors:  Kai Xing; Xitong Zhao; Yibing Liu; Fengxia Zhang; Zhen Tan; Xiaolong Qi; Xiangguo Wang; Hemin Ni; Yong Guo; Xihui Sheng; Chuduan Wang
Journal:  Animals (Basel)       Date:  2020-04-05       Impact factor: 2.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.